Dilon Diagnostics has signed an agreement to distribute GE Healthcare’s Discovery NM750b molecular breast imaging system in select markets across the globe.

The Discovery NM750b breast imaging system was developed to offer significant enhancement in lesion detectability, enabling clinicians to image a broad range of patients.

The system can also be used for imaging patients with dense breast, who are expected to be at higher risk for breast cancer.

According to Dilon, the functional imaging will play a crucial role in early detection of breast cancer.

Dilon Diagnostics chairman and CEO Robert Moussa said: "This relationship will enable us to expand our product portfolio and offer a complete spectrum of BSGI/MBI solutions to better meet the needs of our customers."

GE Healthcare nuclear imaging global business manager Nathan Hermony said: "GE believes strongly in this advanced technology and the potential for this type of imaging to improve breast cancer diagnosis.

"Dilon Diagnostics resources will bring further the education and acceptance of Molecular Breast Imaging."

Dilon Diagnostics, a brand of Dilon Technologies, develops and markets medical imaging solutions.

Dilon molecular imaging system is a high-resolution and compact camera that will image small body parts such as the breast, thyroid, parathyroid and bone.

GE Healthcare provides medical imaging, software and IT, patient monitoring and diagnostics services, as well as drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions.